In one trial, ten patients with chronic myeloid leukemia (CML) were treated with a poly-epitopic peptide vaccine and plasmids encoding IL-12 and GM-CSF as adjuvant. Here, CSF2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.